Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Egetis Therapeutics

4.96 SEK

+3.12 %

Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+3.12 %
-15.59 %
-8.07 %
+17.28 %
-29.21 %
-31.94 %
+16.04 %
-8.47 %
-64.19 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
2.1B SEK
Turnover
2.23M SEK
Revenue
46.1M
EBIT %
-714.53 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/2
2026

Annual report '25

29/4
2026

Interim report Q1'26

6/5
2026

General meeting '26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Press releaseyesterday

Egetis Therapeutics flyttas till Nasdaq Stockholms Mid Cap-segment

Egetis Therapeutics
Press releaseyesterday

Egetis Therapeutics to move to the Nasdaq Stockholm Mid Cap segment

Egetis Therapeutics
Press release12/10/2025, 6:00 AM

Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate® Across Central, Eastern, and Southeastern Europe

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release12/10/2025, 6:00 AM

Egetis och Er-Kim expanderar sitt partnerskap för att öka tillgången till Emcitate® i Central-, Öst- och Sydösteuropa

Egetis Therapeutics
Press release12/4/2025, 9:55 AM

Ny publikation påvisar betydelsefulla kliniska fördelar med Emcitate® (tiratricol) vid behandling av resistens mot sköldkörtelhormon beta (RTH-beta)

Egetis Therapeutics
Press release12/4/2025, 9:55 AM

New publication highlights meaningful clinical benefits of Emcitate® (tiratricol) in treating Resistance to Thyroid Hormone Beta

Egetis Therapeutics
Press release12/1/2025, 10:15 AM

Medlemmar av Egetis Ledningsgrupp förvärvar aktier i Egetis

Egetis Therapeutics
Press release12/1/2025, 10:15 AM

Members of Egetis' Leadership Team acquire shares in Egetis

Egetis Therapeutics
Press release11/27/2025, 1:07 PM

Redeye: Egetis (Q3 review) - Focus on US application

Egetis Therapeutics
Press release11/27/2025, 7:40 AM

Egetis Therapeutics styrelseordförande förvärvar aktier

Egetis Therapeutics
Press release11/27/2025, 7:40 AM

Chairman of the Board of Egetis Therapeutics acquires shares

Egetis Therapeutics
Press release11/26/2025, 2:18 PM

BioStock: Egetis stärker den regulatoriska vägen för Emcitate efter positiva ReTRIACt-data

Egetis Therapeutics
Press release11/26/2025, 2:18 PM

BioStock: Egetis strengthens regulatory path for Emcitate following positive ReTRIACt data

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Q3'25
Webcast11/25/2025, 9:00 AM

Egetis Therapeutics, Audiocast, Q3'25

Egetis Therapeutics
Regulatory press release11/25/2025, 6:00 AM

Kvartalsrapport Q3 2025

Egetis Therapeutics
Regulatory press release11/25/2025, 6:00 AM

Interim report Q3 2025

Egetis Therapeutics
Press release11/21/2025, 1:40 PM

Inbjudan till presentation av Egetis kvartalsrapport Q3 2025 den 25 november 2025

Egetis Therapeutics
Press release11/21/2025, 1:40 PM

Invitation to Presentation of Egetis’ Third Quarter 2025 Report on November 25, 2025

Egetis Therapeutics
Egetis Therapeutics, Audiocast, 2025
Webcast11/14/2025, 9:00 AM

Egetis Therapeutics, Audiocast, 2025

Egetis Therapeutics
Regulatory press release11/14/2025, 6:00 AM

Egetis meddelar positiva resultat från ReTRIACt-studien med Emcitate® (tiratricol) vid MCT8-brist

Egetis Therapeutics
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.